What's Happening?
Croma-Pharma has announced its return to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product used in the treatment of knee osteoarthritis. This move marks a strategic expansion for Croma-Pharma, which had previously
been active in orthopaedics until 2014. Synocrom™ is a well-established product in Europe, known for its role in joint lubrication and function, potentially alleviating symptoms of degenerative joint changes. The product will be available in the EU and Switzerland from May 2026, reflecting Croma-Pharma's commitment to providing high-quality medical solutions.
Why It's Important?
The reacquisition of Synocrom™ by Croma-Pharma is significant as it represents the company's strategic re-entry into the orthopaedics market, a field where it has historical roots. This move not only broadens Croma-Pharma's portfolio but also reinforces its position as a leader in the development and manufacturing of hyaluronic acid products. The availability of Synocrom™ in the EU and Switzerland will provide healthcare professionals with a reliable option for treating knee osteoarthritis, a common condition that affects many individuals, thereby potentially improving patient outcomes and quality of life.
